Component: (Network and Table)
Network
00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(http://www.alkermes.com/role/StatementCondensedConsolidatedStatementsOfCashFlows)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001520262 (http://www.sec.gov/CIK)
STATEMENTS OF CASH FLOWS DATA:Period [Axis]
2016-01-01 - 2016-12-31
2015-01-01 - 2015-12-31
2014-01-01 - 2014-12-31
STATEMENTS OF CASH FLOWS DATA:
 
 
 
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net loss
(208,444,000) 
(227,163,000) 
(30,061,000) 
Adjustments to reconcile net loss to cash flows from operating activities:
 
 
 
Depreciation and amortization
94,256,000  
85,596,000  
98,087,000  
Share-based compensation expense
94,396,000  
97,341,000  
59,579,000  
Deferred income taxes
(9,689,000) 
(37,580,000) 
(19,192,000) 
Excess tax benefit from share-based compensation
(4,229,000) 
(28,576,000) 
(32,367,000) 
Gain on sale of investment in Civitas Therapeutics, Inc.
  
(29,564,000) 
Gain on the Gainesville Transaction
 
(9,636,000) 
 
Change in the fair value of contingent consideration
(7,900,000) 
2,300,000  
 
Loss on debt refinancing
2,075,000  
  
Gain on sale of property, plant and equipment
 
(3,272,000) 
(40,099,000) 
Gain on sale of investment of Acceleron Pharma Inc.
  
(15,296,000) 
Other non-cash charges
2,936,000  
 
9,192,000  
Other non-cash charges
 
(1,351,000) 
 
Changes in assets and liabilities (excluding the effect of dispositions):
 
 
 
Receivables
(35,616,000) 
(16,455,000) 
(17,397,000) 
Inventory
(26,381,000) 
3,687,000  
(4,210,000) 
Prepaid expenses and other assets
(15,014,000) 
15,931,000  
(27,027,000) 
Accounts payable and accrued expenses
45,870,000  
76,155,000  
56,896,000  
Deferred revenue
(649,000) 
(629,000) 
(996,000) 
Other long-term liabilities
4,587,000  
3,292,000  
3,594,000  
Cash flows (used in) provided by operating activities
(63,802,000) 
 
(40,360,000) 
 
11,139,000  
 
CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Additions of property, plant and equipment
(43,657,000) 
(52,877,000) 
(33,651,000) 
Proceeds from the sale of equipment
194,000  
535,000  
44,365,000  
Investment in Reset Therapeutics, Inc.
(15,000,000) 
  
Purchases of investments
(375,099,000) 
(508,683,000) 
(642,455,000) 
Sales and maturities of investments
560,805,000  
467,573,000  
341,154,000  
Net proceeds from the Gainesville Transaction
 
49,966,000  
 
Investment in Civitas Therapeutics, Inc.
  
27,190,000  
Cash flows provided by (used in) investing activities
127,243,000  
 
(43,486,000) 
 
(263,397,000) 
 
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Proceeds from the issuance of ordinary shares, net
  
248,406,000  
Proceeds from the issuance of ordinary shares under share-based compensation arrangements
20,308,000  
44,969,000  
47,577,000  
Excess tax benefit from share-based compensation
4,229,000  
28,576,000  
32,367,000  
Employee taxes paid related to net share settlement of equity awards
(13,467,000) 
(25,904,000) 
(12,840,000) 
Payment made for debt refinancing
(3,429,000) 
  
Principal payments of long-term debt
(65,813,000) 
(6,750,000) 
(6,750,000) 
Cash flows (used in) provided by financing activities
(58,172,000) 
 
40,891,000  
 
308,760,000  
 
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
5,269,000  
 
(42,955,000) 
 
56,502,000  
 
CASH AND CASH EQUIVALENTS - Beginning of period
181,109,000  
224,064,000  
167,562,000  
CASH AND CASH EQUIVALENTS - End of period
186,378,000  
 
181,109,000  
 
224,064,000  
 
SUPPLEMENTAL CASH FLOW DISCLOSURE:
 
 
 
Cash paid for interest
12,458,000  
12,323,000  
12,489,000  
Cash paid for taxes
5,531,000  
705,000  
2,799,000  
Non-cash investing and financing activities:
 
 
 
Purchased capital expenditures included in accounts payable and accrued expenses
5,766,000  
6,054,000  
3,483,000  
Fair value of warrants received as part of the Gainesville Transaction
 
2,123,000  
 
Fair value of contingent consideration received as part of the Gainesville Transaction
 
57,600,000